The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.

[1]  E. Tan,et al.  Case-control study of hypertension and Parkinson’s disease , 2021, npj Parkinson's Disease.

[2]  C. Vlachopoulos,et al.  Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson’s Disease—a Systematic Review , 2021, Current Hypertension Reports.

[3]  Zi-hui Meng,et al.  Design, Synthesis, and Biological Activity Studies of Istradefylline Derivatives Based on Adenine as A2A Receptor Antagonists , 2021, ACS omega.

[4]  R. Hauser,et al.  Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease , 2021, Expert review of neurotherapeutics.

[5]  A. Kaye,et al.  Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review , 2020, Neurology international.

[6]  C. Pu,et al.  Targeting continuity of care and polypharmacy to reduce drug–drug interaction , 2020, Scientific Reports.

[7]  M. Artifoni,et al.  Resistant Hypertension: Novel Insights. , 2020, Current hypertension reviews.

[8]  K. Williams,et al.  Hypertension in older adults: Assessment, management, and challenges , 2019, Clinical cardiology.

[9]  G. Hu,et al.  Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro , 2019, Front. Pharmacol..

[10]  M. Cantillon,et al.  Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects , 2017, Journal of clinical pharmacology.

[11]  G. Hu,et al.  Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro , 2017, Drug design, development and therapy.

[12]  D. Dai,et al.  Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. , 2017, Pharmacogenomics.

[13]  S. Kato,et al.  Posterior reversible encephalopathy syndrome in Parkinson disease probably caused by prominent supine hypertension and blood pressure fluctuation. , 2016, Rinsho shinkeigaku = Clinical neurology.

[14]  A. Antonini,et al.  The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease , 2015, Expert review of neurotherapeutics.

[15]  T. Müller.  The safety of istradefylline for the treatment of Parkinson’s disease , 2015, Expert opinion on drug safety.

[16]  I. Cascorbi,et al.  Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.

[17]  D. Dexter,et al.  Parkinson disease: from pathology to molecular disease mechanisms. , 2013, Free radical biology & medicine.

[18]  T. Müller.  Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations , 2013, Expert opinion on drug metabolism & toxicology.

[19]  Hongquan Wang,et al.  Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis , 2013, Journal of the Neurological Sciences.

[20]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.

[21]  M. Stacy,et al.  Istradefylline for the treatment of Parkinson's disease , 2012, Expert opinion on pharmacotherapy.

[22]  Songnian Hu,et al.  Analysis of CYP3A4 genetic polymorphisms in Han Chinese , 2011, Journal of Human Genetics.

[23]  N. Srinivas.  Efflux Transporter‐Mediated Interactions With Atorvastatin—Interesting Findings With Multiple Substrates: Istradefylline, Verapamil, and Rifampicin , 2009, Journal of clinical pharmacology.

[24]  B. Dvorchik,et al.  A Study of the Pharmacokinetic Interaction of Istradefylline, a Novel Therapeutic for Parkinson's Disease, and Atorvastatin , 2008 .

[25]  D. Tomassoni,et al.  Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies , 2008, Clinical and experimental hypertension.

[26]  R. V. van Schaik,et al.  CYP450 pharmacogenetics for personalizing cancer therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  A. B. Ruzilawati,et al.  Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[28]  Lin He,et al.  Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. , 2006, Pharmacogenomics.

[29]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.